Some breast cancer cell lines, such as T-47D and MCF7, were slightly more sensitive than the NSCLC cell lines to the PI3K inhibitor, likely due to mutations in the kinase and helical domains (Figure 1A; Table 1). This evidence concerns the gene PIK3CD and non-small cell lung carcinoma.